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Introduction {#sec1}
============

Cancer stem cells (CSCs) are a subpopulation of tumor cells capable of self-renewal and extensive proliferation. These properties make CSCs one of the driving forces in each of the cancer processes including progression, recurrence, and metastasis ([@bib43]). Accumulating evidence also suggests that CSCs play paramount roles in the development of therapeutic resistance ([@bib30], [@bib43]). Given the fact that the overwhelming majority of cancer recurrences are due to the repopulation of cancer cells from CSCs, targeting CSCs would be an efficacious strategy in the development of treatments for therapeutic resistant cancers ([@bib30]). Thus, better understanding the underlying molecular mechanisms in both cancer development and maintenance of cancer stemness will provide strategies in designing new cancer treatments. An increasing body of evidence suggests that epigenetic changes play critical roles in the development of cancer stemness ([@bib10]). Epigenetic mechanisms such as histone modifications, DNA methylation, chromatin remodeling, and even changes in noncoding RNAs including long non-coding RNAs (lncRNAs) govern the epigenetic landscape that dictates the outcomes of cell fates without changing the DNA sequence ([@bib22]). Akin to embryonic stem cells, CSCs undergo similar epigenetic processes such as DNA methylation and chromatin remodeling ([@bib10]).

lncRNAs are a subgroup of RNA molecules that are more than 200 nucleotides in length without encoding any protein ([@bib33]). It has been estimated that lncRNAs represent approximately 80% of the eukaryotic transcriptome, and the roles of lncRNAs have just started to be recognized ([@bib33]). LncRNAs can have either tumor-suppressing or tumor-promoting activities, and genome-wide association studies of different tumor samples found that mutations and/or altered expressions of lncRNA could be responsible for both tumorigenesis and metastasis ([@bib33]). Therefore, it has been suggested that the levels of some lncRNAs could be used as potential biomarkers and targeting lncRNAs could be developed into efficient cancer treatments ([@bib4]). SOX2OT (SOX2 overlapping transcript) is a lncRNA and directly involved in the regulation of SOX2, one of the master regulators crucial for both embryonic stem cells and cancer stemness ([@bib26], [@bib50]). It has been noticed that not only is SOX2OT co-upregulated with SOX2 in multiple cancers including esophageal squamous cell carcinoma ([@bib35]), lung squamous cell carcinoma ([@bib18]), and breast cancer ([@bib1]), but also upregulated SOX2OT and SOX2 also highly associate with poor outcome ([@bib18], [@bib50]). Of note, both SOX2OT and SOX2 are amplified in esophageal squamous cell carcinoma (ESCC) ([@bib3], [@bib44]), although little is known about the regulation of the SOX2OT/SOX2 axis in this particular cancer.

By being involved in chromatin remodeling ([@bib20]), metastasis-associated proteins (MTAs) composed of MTA1, MTA2, and MTA3 ([@bib39]) serve as master regulators in both physiological and pathological contexts ([@bib31]). All family members of the MTA are associated with the NuRD complex to suppress a subset of target genes ([@bib5], [@bib28], [@bib47]). Although both MTA1 and MTA2 are generally considered as oncogenes mainly because they are capable of enhancing metastasis, MTA3 can serve as either a cancer repressor or an oncogene depending on cancer types ([@bib31]). MTA3 was initially discovered as an estrogen-dependent gene that forms a distinct complex with Mi-2/NuRD and possesses strong transcription repressing activity on Snai1, leading to the upregulation of E-cadherin, and subsequently inhibits invasive growth of breast cancer cells ([@bib49]). In addition, downregulation of MTA3 is associated with poor prognosis in a variety of cancers, including gastroesophageal junction adenocarcinoma ([@bib11]), endometrioid adenocarcinomas ([@bib7]), and brain glioma ([@bib36]). On the other hand, upregulation of MTA3 in uterine non-endometrioid ([@bib29]) and non-small cell lung cancer ([@bib24]) is significantly correlated with poor prognosis. Of note, it has been suggested that MTA3-mediated epigenetic remodeling of chromatins may be involved in the regulation of cancer stemness ([@bib27]).

In this study, we explored the roles and the underlying molecular mechanisms of MTA3 in ESCC based on the following reasons: (1) ESCC is one of the major cancers in the digestive tract ([@bib13], [@bib14]) with 26%--53% of patients showing lymph node metastasis ([@bib19]); (2) it appears that MTA3 utilizes a totally different EMT-regulating mechanisms in ESCC. We found that, in ESCC cells, MTA3 inhibits cancer stemness and metastasis by targeting the SOX2OT/SOX2 axis.

Results {#sec2}
=======

Downregulation of MTA3 Correlates with Tumor Progression and Poor Prognosis in Human ESCC {#sec2.1}
-----------------------------------------------------------------------------------------

To systematically explore the roles of MTA3 in cancer initiation and progression, we first examined the protein levels of MTA3 in different organs based on the dataset obtained from the Human Protein Atlas database ([www.proteinatlas.org](http://www.proteinatlas.org){#intref0010}) and found that MTA3 is almost ubiquitously expressed. However, its expression is particularly high in the gastrointestinal (GI) digestive tract including esophagus ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), suggesting that MTA3 may play more important roles in these tissues. Results from analyzing the dataset GSE26886 showed that compared with that in normal esophageal epithelium tissues (n = 19) the mRNA levels of MTA3 are significantly lower in multiple GI tract diseases including ESCC tissues (n = 9), esophagus adenocarcinoma (n = 21), and Barrett esophagus (n = 20) (p \< 0.001 for all; [Figure S1](#mmc1){ref-type="supplementary-material"}C). In addition, a different dataset (GSE23400) also showed lower MTA3 mRNA levels in high percentage tumors (35/51) compared with their paired normal adjacent tissues (p \< 0.01; [Figure 1](#fig1){ref-type="fig"}A). We then conducted qRT-PCR to estimate the mRNA levels of *MTA3* in ESCC patient samples and found that compared with their paired normal adjacent tissues 10 of 15 ESCC tissues expressed lower levels of *MTA3* mRNA ([Figure 1](#fig1){ref-type="fig"}B). We also conducted western blot assays to compare the protein levels of MTA3 in ESCC cell lines with two immortalized normal esophageal epithelial cell lines, NE2 and NE3. [Figure 1](#fig1){ref-type="fig"}C shows that all cancer cell lines examined express lower levels of MTA3. This finding is also consistent with the notion that ESCC cell lines express lower levels of MTA3 than that of normal esophageal epithelium cells (dataset GSE23964) ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These data altogether suggest that MTA3 may play some anti-cancer roles in ESCC.Figure 1Downregulation of MTA3 Correlates with Poor Prognosis in Human ESCC(A) The mRNA levels of *MTA3* in the ESCC dataset GSE23400.(B) The mRNA levels of *MTA3* in 15 human ESCC specimens and their paired normal adjacent tissues.(C) Western blot analysis of MTA3 in a panel of ESCC cell lines and two immortalized esophageal epithelial cell lines. β-Actin is used as a loading control.(D) Immunohistochemistry (IHC) of MTA3 in 125 human ESCC tissues and their paired adjacent normal tissues (left panel). The immunohistochemistry score of MTA3 in ESCC (filled bar) and the paired normal adjacent (open bar) tissues (right panel). Scale bars: upper panels, 400 μm; lower panels, 100 μm.(E) Receiver operating characteristic (ROC) curve analysis to determine the cutoff score for low expression of MTA3.(F) Kaplan-Meier curves compared the overall survival in patients with ESCC with high and low protein levels of MTA3.(G) GSEA plots of enrichment of BIOCARTA_MTA3_PATHWAY in normal adjacent tissues versus ESCC specimens in the GSE23400 dataset. FDR q, false-discovery rate q value; NES, normalized enrichment score.Data were shown as the means from at least three independent experiments or representative data. Error bars indicate SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 by Student\'s t test. See also [Figure S1](#mmc1){ref-type="supplementary-material"}, [Table S1](#mmc1){ref-type="supplementary-material"}, and [Table S2](#mmc1){ref-type="supplementary-material"}.

To determine the clinical relevance of MTA3 in ESCC, we conducted immune-histochemical analyses to compare the protein levels of MTA3 in 125 ESCC tissues with their paired normal adjacent tissues and found that MTA3 is significantly lower in ESCC tissues (p \< 0.001; [Figure 1](#fig1){ref-type="fig"}D). In addition, according to the receiver operating characteristic (ROC) curve ([Figure 1](#fig1){ref-type="fig"}E) with an optimal cutoff point of 4.25 (H-score) we found that 62.4% (78 of 125) of ESCC tissues versus only 12.5% (16 of 125) adjacent normal tissues had lower levels of MTA3. Furthermore, correlation analyses revealed that the protein levels of MTA3 are inversely correlated with both tumor depth (p = 0.011; [Table S1](#mmc1){ref-type="supplementary-material"}) and advanced clinical stages (p = 0.033; [Table S1](#mmc1){ref-type="supplementary-material"}). More importantly, Kaplan-Meier analyses showed that patients with ESCC with a lower level of MTA3 are associated with poorer prognosis (p = 0.001; [Figure 1](#fig1){ref-type="fig"}F) and multivariate Cox regression analyses showed that MTA3 can serve as an independent prognostic factor for overall survival of patients with ESCC (hazard ratio \[HR\], 2.717; 95% confidence interval \[CI\], 1.333--5.537, p = 0.006; [Table S2](#mmc1){ref-type="supplementary-material"}). Finally, gene set enrichment analysis (GSEA) found that, compared with the paired normal adjacent tissues, the signature that negatively correlated with MTA3 is enriched in ESCC tissues (dataset GSE23400) (p = 0.023, false discovery rate \[FDR\] = 0.043; [Figure 1](#fig1){ref-type="fig"}G). Taken together, these data suggest that MTA3 might possess a repressive role in ESCC progression.

MTA3 Suppresses ESCC Cell Metastasis and Stemness {#sec2.2}
-------------------------------------------------

To gain insights into the potential repressive role of MTA3 in ESCC progression, we conducted GSEA on the dataset GSE23400 to explore the downstream signaling of MTA3 and found that MTA3 expression is inversely related to the metastatic signatures (p = 0.024, FDR = 0.035; [Figure S2](#mmc1){ref-type="supplementary-material"}A). We chose four cell lines to examine the effect of MTA3 on the metastasis makers and found that knockdown MTA3 in ESCC cells leads to significant reduction and induction of the epithelial marker (E-cadherin) and mesenchymal markers (N-cadherin and vimentin), respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}B). On the other hand, overexpression of MTA3 showed the exact opposite effects on these markers ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These results support the notion that MTA3 may be involved in the regulation of ESCC cell metastasis. In addition, MTA3 knockdown not only makes the actin filaments in cells more elongated stress fibers but more cells also lost their cell-cell contacts ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The fluorescent phalloidin staining results also showed that overexpression of MTA3 altered the shape of cells from spindle-like, fibroblastic morphology to a cobblestone-like appearance ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The more flexible cytoskeleton of neoplastic is expected to favor cell migration through the trans-well, and indeed the trans-well assays showed that more MTA3-depleted cells migrated through the membrane (p \< 0.05 for all; [Figure S2](#mmc1){ref-type="supplementary-material"}D). In contrast, MTA3 overexpression suppressed both ESCC cell invasion and migration (p \< 0.001 for both; [Figure S2](#mmc1){ref-type="supplementary-material"}D). These data collectively demonstrated that MTA3 possesses a repressive role in ESCC cell metastasis.

Before conducting experiments to determine the MTA3\'s effect on ESCC metastasis *in vivo*, GSEA analyses on two separate datasets were conducted to determine the effect of MTA3 on tumor cell proliferation and lymph node invasion. We found that (1) MTA3 expression was inversely related to cell proliferation (dataset GSE23400) (p = 0.027, FDR = 0.032; [Figure S3](#mmc1){ref-type="supplementary-material"}A) and (2) ESCC tissues with low MTA3 activity are more intend to have lymph node metastasis (dataset GSE47404) (p = 0.032, FDR = 0.041; [Figure S3](#mmc1){ref-type="supplementary-material"}B). Then we estimated the effect of MTA3 on ESCC cells using the *in vivo* animal model. [Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D showed that tumors derived from EC9706 and EC109 cells were not only larger but also heavier when MTA3 is knocked down by shRNA (p \< 0.01 for all). On the other hand, the tumors derived from EC9706 and HKESC-1 cells were smaller and lighter when MTA3 is overexpressed (p \< 0.01 for both; [Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). These results indicate that MTA3 can repress ESCC cell proliferation *in vivo*. In addition and consistent with the *in vitro* data, epithelial marker (E-cadherin) and mesenchymal markers (N-cadherin and Vimentin) in tumors derived from ESCC cells were significantly decreased and increased, respectively, when MTA3 was knocked down ([Figure S3](#mmc1){ref-type="supplementary-material"}G). This suggests that MTA3 can repress ESCC cell metastasis *in vivo*. To further substantiate this finding, the EC9706 and TE1 cells with or without shMTA3 transfection were labeled with luciferase and injected into the flanks of nude mice ([Figures 2](#fig2){ref-type="fig"}A, [S3](#mmc1){ref-type="supplementary-material"}H, and S3I). The expression of luciferase enabled us to monitor the tumor cell dissemination and inguinal lymph node metastasis. We found that depletion of MTA3 promoted inguinal lymph node metastasis ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S3](#mmc1){ref-type="supplementary-material"}J), which is further substantiated by hematoxylin and eosin (H&E) staining ([Figure 2](#fig2){ref-type="fig"}F). Finally, when these cells were injected into the tail vein of nude mice, more ESCC cells in the MTA3 knockdown group were found in the lungs ([Figure 2](#fig2){ref-type="fig"}D and 2E), which is substantiated with results of H&E staining ([Figure 2](#fig2){ref-type="fig"}G). These findings altogether lead us to conclude that MTA3 plays an important repressive role in ESCC cell proliferation and metastasis *in vivo*.Figure 2MTA3 Suppresses Metastasis and Stemness of ESCC Cells(A) EC9706 cells transfected with shMTA3 or shCtrl were infected with lentiviruses carrying luciferase and then subjected to RNA extraction followed by qRT-PCR analysis of luciferase gene.(B--G) The EC9706 cells with or without MTA3 depletion were infected with recombinant lentiviruses carrying luciferase and injected subcutaneously into the flanks of nude mice (n = 8). The inguinal lymph nodes of the animals were extracted and analyzed for the presence of metastatic cells by bioluminescence imaging (B), and proportion of inguinal lymph nodes metastasis in the nude mice (C). EC9706 cells transfected with shMTA3 or shCtrl were injected intravenously through the tail vein of nude mice (n = 6). Representative images of lung metastasis were shown (D, left panel), numbers of metastatic nodules per lung in the nude mice (D, right panel), and proportion of lung metastasis in the nude mice (E). (F) The inguinal lymph nodes were analyzed by H&E. Scale bars: left panels, 400 μm; right panels, 100 μm. (G) Lung architecture is shown by H&E. Scale bars: left panels, 400 μm; right panels, 100 μm.(H) GSEA plots of enrichment of BOQOEST_STEM_CELL_UP signatures in MTA3^High^ tumors versus MTA3^Low^ tumors in the GSE23400 dataset.(I) Representative images of spheres formed by EC9706 cells with MTA3 depleted (upper panel) or overexpressed (lower panel). Histograms showing the fold change in the number of spheres formed by EC9706 cells with MTA3 depleted (upper right panel) or overexpressed (lower right panel). Scale bars: 200 μm.(J--L) (J) Flow cytometry analysis of the CD44^+^ population in EC9706 cells with MTA3 depleted (upper panel) or overexpressed (lower panel). Histograms showing the proportion of CD44^+^ cells in EC9706 cells with MTA3 depleted (upper right panel) or overexpressed (lower right panel). (K and L) Hoechst 33342 dye exclusion assay of the SP^+^ population in EC9706 cells with MTA3 depleted (K) or overexpressed (L). Histograms showing the proportion of SP^+^ cells in EC9706 cells with MTA3 depleted (K, right panel) or overexpressed (L, right panel).(M) Representative images of immunofluorescence for CD44 proportion in EC9706 cells with MTA3 depleted. Scale bars: 40 μm.Data are shown as the means of three independent experiments or representative data. Error bars indicate SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 by Student\'s t test or chi-square test, where appropriate. See also [Figures S2--S5](#mmc1){ref-type="supplementary-material"}.

Since merging evidence points toward a central role of MTA3 in epithelial to mesenchymal transition (EMT) by targeting Snai1 ([@bib15]), we decided to determine whether MTA3 is involved in the regulation of Snai1 in ESCC cells. To do so, we conducted qRT-PCR to estimate the mRNA levels of Snai1 and the other EMT-related transcriptional factors including Twist 1, Twist2, and ZEB1 in three ESCC cell lines (EC9706, EC109, and TE1) with or without MTA3 knockdown. As shown in [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D, knockdown MTA3 in these cells has no effect on any of these factors in both RNA and protein levels. Then a luciferase reporter plasmid under the control of promoter of the Snai1 gene was transfected to these three cell lines with or without MTA3 knockdown. Consistent with the qRT-PCR results, knockdown MTA3 has no effect on luciferase activity under the control of the Snai1 promoter ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G). Therefore, we assumed that the effect of MTA3 on ESCC metastasis is through regulatory mechanisms other than these EMT regulators. CSCs are a small subpopulation of cells in the cancer tissue and play important roles in every aspect of cancer development, including initiation, progression, and metastasis. To explore whether MTA3 plays any role in CSCs, we conducted a GSEA on dataset GSE23400 and found that MTA3 is inversely associated with stemness signatures (p = 0.049, FDR = 0.067; [Figure 2](#fig2){ref-type="fig"}H). We then estimated MTA3\'s effect on mammosphere formation and found that knockdown and overexpression of MTA3 significantly (p \< 0.01) increased and decreased the number of mammospheres, respectively ([Figures 2](#fig2){ref-type="fig"}I and [S5](#mmc1){ref-type="supplementary-material"}A), suggesting that MTA3 possesses property against ESCC cancer stemness. To substantiate these findings, we estimated MTA3\'s effects on the CD44^+^ and side population (SP) cells ([@bib8]) and found that depletion of MTA3 significantly (p \< 0.001) increased the proportion of both CD44^+^ ([Figures 2](#fig2){ref-type="fig"}J and [S5](#mmc1){ref-type="supplementary-material"}B) and SP^+^ ([Figures 2](#fig2){ref-type="fig"}K and [S5](#mmc1){ref-type="supplementary-material"}C) cells, whereas overexpression of MTA3 decreased the proportion of both CD44^+^ ([Figures 2](#fig2){ref-type="fig"}J and [S5](#mmc1){ref-type="supplementary-material"}B) and SP^+^ cells ([Figure 2](#fig2){ref-type="fig"}L). Finally, CD44 increased dramatically in ESCC cells when MTA3 is knocked down ([Figures 2](#fig2){ref-type="fig"}M and [S5](#mmc1){ref-type="supplementary-material"}D). Of note, the role of MTA3 in ESCC cancer stemness was supported by the findings in other tumors, including head and neck squamous cell carcinoma (HNSCC), oral squamous cell carcinoma (OSCC), breast invasive carcinoma (BRCA), and pancreatic adenocarcinoma (PAAD) datasets ([Figures S5](#mmc1){ref-type="supplementary-material"}E--S5H).

MTA3 Downregulates SOX2 and SOX2OT Simultaneously {#sec2.3}
-------------------------------------------------

To understand the mechanism in MTA3-regulated ESCC cancer stemness, we conducted a stemness PCR array and found that MTA3 knockdown leads to certain stemness-related genes to be up- or down-regulated, and 11 of them were elevated more than 1.5-fold ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Results from analyzing these 11 genes in the Cancer Genome Atlas (TCGA) database suggested that CHEK1, SOX2, and TAZ were significantly upregulated in ESCC tissues ([Figure S6](#mmc1){ref-type="supplementary-material"}B). We then conducted qRT-PCR on these three genes and found that only SOX2, not the other two, is significantly up- and down-regulated by MTA3 depletion and overexpression, respectively ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). In addition, western blot assays also confirmed that MTA3 downregulates SOX2 in ESCC cells ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Given the pivotal roles of SOX2 in both embryonic and cancer stemness ([@bib3], [@bib26]), we examined MTA3\'s effect on SOX2 expression. However, luciferase reporter assays showed that MTA3 has no regulatory effect on SOX2 promoter ([Figures S6](#mmc1){ref-type="supplementary-material"}F and S6G), suggesting that MTA3 could regulate SOX2 indirectly.

SOX2 overlapping transcript (SOX2OT) is a lncRNA located in the intron of the SOX2 gene ([@bib26]) and transcribed in the same orientation of SOX2. It has been reported that SOX2OT is co-upregulated with SOX2 in ESCC cells ([@bib35]), and upregulation of SOX2OT and SOX2 is involved in the regulation of cancer stemness ([@bib26]). Mechanistically, SOX2OT upregulates SOX2 by serving as a competing endogenous RNA (ceRNA) to sequester specific microRNA (miRNA) and subsequently counteract miRNA-mediated SOX2 downregulation ([@bib26]). We decided to determine if MTA3 represses SOX2 expression via targeting SOX2OT. We found that MTA3 knockdown and overexpression significantly (p \< 0.01) up- and down-regulated both SOX2OT and SOX2, respectively (p \< 0.01, [Figures 3](#fig3){ref-type="fig"}A--3D). Finally, we conducted luciferase reporter assays to determine MTA3\'s regulatory role in SOX2OT transcription. [Figure 3](#fig3){ref-type="fig"}E demonstrated that MTA3 is capable of repressing SOX2OT promoter activity because of depletion and overexpression of MTA3 significantly up- and down-regulated the reporter activity, respectively (p \< 0.001 for both). Together, these data suggest that, in ESCC cells, MTA3 indirectly downregulates SOX2 by targeting SOX2OT.Figure 3MTA3 Inhibits SOX2OT Transcription Depending on GATA3(A) QRT-PCR of SOX2OT in EC9706 cells with MTA3 depletion or MTA3 overexpression and in HKESC-1 cells with MTA3 overexpression.(B--D) Western blot of SOX2 and qRT-PCR of SOX2OT in tumors derived from EC9706 (B) and EC109 (C) cells with MTA3 depletion, or EC9706 cells and HKESC-1 cells with MTA3 overexpression (D).(E) SOX2OT *Gaussia* luciferase reporter activity in EC9706 cells with MTA3 depletion or overexpression.(F) Schematic structure of the SOX2OT promoter and positions of ChIP primers.(G) Proximity Ligation Assay (PLA) detection of MTA3-GATA3 interaction. EC9706 cells transfected with the indicated shRNAs were subjected to PLA using antibodies against MTA3 or GATA3. Scale bars: 10 μm.(H and I) ChIP assay using antibodies against MTA3 or IgG. Semi-quantitative PCR (H) and qPCR (I) to detect the enriched DNA fragments in the SOX2OT promoter region.(J) Western blot of GATA3 in MTA3 overexpressed EC9706 cells transfected with shGATA3-expressing plasmid. β-Actin is shown as a loading control.(K) SOX2OT luciferase reporter activity in EC9706 cells transfected with the MTA3 or shGATA3 plasmids.(L) ChIP assay was performed in EC9706 cells with GATA3 depletion using antibodies against MTA3 or IgG, and qPCR was used to detect the enriched DNA fragments in the SOX2OT promoter region.(M) Schematic structure of deletion-mutation reporters of the SOX2OT promoter.(N and O) The SOX2OT promoter-reporter and mutations ΔGATA3 (N) or in GATA3-binding site 1 (ΔGATA3 \#1), GATA3-binding site 2 (ΔGATA3 \#2), GATA3-binding site 3 (ΔGATA3 \#3) (O). The relative SOX2OT Gaussia luciferase reporter activities 72 h after transfection.Data are shown as the means of three independent experiments or representative data. Error bars indicate SEM, n.s., not statistically significant; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by Student\'s t test or a one-way ANOVA with post hoc intergroup comparisons, where appropriate. See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}, and [Table S3](#mmc1){ref-type="supplementary-material"}.

MTA3 Is Recruited by GATA3 to Repress SOX2OT Transcription {#sec2.4}
----------------------------------------------------------

Although MTA3 harbors a putative DNA-binding domain, there is no evidence indicating that MTA3 can interact with DNA directly ([@bib20]). Since it has been reported that MTA3 can serve as a transcriptional repressor by complexing with GATA3 ([@bib37]), we conducted bioinformatics analyses using PROMO (<http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3>) and JASPAR (<http://jaspar.genereg.net/>) and found three potential GATA3-binding sites in the promoter region of SOX2OT gene ([Figure 3](#fig3){ref-type="fig"}F). We then conducted a simple duo-link assay and found that MTA3 is very likely to complex with GATA3 in ESCC cells ([Figure 3](#fig3){ref-type="fig"}G). To determine whether MTA3 is recruited to the promoter of SOX2OT, we performed chromatin immunoprecipitation (ChIP) assays using an antibody against MTA3 and the precipitated DNA was amplified with different pairs of primers ([Figure 3](#fig3){ref-type="fig"}F). Results from both semi-quantitative PCR ([Figure 3](#fig3){ref-type="fig"}H) and qPCR ([Figures 3](#fig3){ref-type="fig"}I and [S7](#mmc1){ref-type="supplementary-material"}A) demonstrated that MTA3 is recruited to the promoter region of the SOX2OT gene by GATA3 because knockdown of GATA3 abolished MTA3\'s repressive effect on SOX2OT and inhibited the MTA3\'s occupation on the promoter region of SOX2OT ([Figures 3](#fig3){ref-type="fig"}J--3L, [S7](#mmc1){ref-type="supplementary-material"}B, and S7C). To determine which GATA3-binding site(s) is responsible for MTA3 recruitment, we conducted luciferase reporter assays with one, two, or three potential GATA3 being deleted ([Figure 3](#fig3){ref-type="fig"}M) from the SOX2OT promoter. [Figure 3](#fig3){ref-type="fig"}N shows that MTA3 failed to repress SOX2OT promoter activity when these potential GATA3 sites were deleted. In addition, potential GATA3-binding site \#1 is likely to be not involved in MTA3 recruitment because deletion of this site has no effect on MTA3-mediated repression. However, sites \#2 and \#3 are likely to be responsible for the recruitment of GATA3/MTA3 complex because deleting either of them reduced MTA3-mediated repression significantly (p \< 0.001, [Figure 3](#fig3){ref-type="fig"}O). These results collectively demonstrated that, in ESCC cells, MTA3 is recruited by GATA3 to inhibit SOX2OT expression.

MTA3 Represses Metastasis and Cancer Stemness by Targeting the SOX2OT/SOX2 Axis {#sec2.5}
-------------------------------------------------------------------------------

To determine if MTA3-repressed cancer stemness is mediated by the SOX2OT/SOX2 axis, we first examined the role of SOX2OT in MTA3-regulated EMT, invasion, and stemness by analyzing the changes of specific markers in the presence or absence of SOX2OT. [Figure 4](#fig4){ref-type="fig"}A showed that SOX2OT was successfully knocked down by locked nucleic acid (LNA)-modified antisense oligonucleotides (GapmeRs), which is referred as SOX2OT AS. As expected, knockdown of SOX2OT leads to a reduced level of SOX2. [Figure 4](#fig4){ref-type="fig"}A also showed that knockdown of MTA3 not only leads to higher levels of both SOX2 and SOX2OT but also altered the EMT and stemness markers accordingly. Of note, MTA3-depletion-mediated SOX2 upregulation is significantly reduced when SOX2OT is depleted, suggesting that SOX2OT plays a crucial role in MTA3-mediated SOX2 repression. We have also examined the effect of overexpression of either SOX2OT or MTA3 individually or in combination on SOX2 and specific markers. [Figure 4](#fig4){ref-type="fig"}B showed that overexpressed SOX2OT and MTA3 were able to up- and down-regulate SOX2, respectively. However, overexpressed SOX2OT is capable of counteracting MTA3-repressed SOX2 expression as well as the alteration of EMT and stemness markers. In addition, [Figures 4](#fig4){ref-type="fig"}C and 4D show that SOX2OT promotes both cell invasion and cancer stemness and MTA3 represses these processes by inhibiting SOX2OT. These observations are consistent with the effect of SOX2OT and MTA3 on the subpopulations of CD44^+^ and SP^+^ cells ([Figure S8](#mmc1){ref-type="supplementary-material"}). More importantly, overexpressed MTA3 inhibited SOX2OT-induced inguinal lymph node metastasis ([Figures 4](#fig4){ref-type="fig"}E and 4F). These data altogether demonstrated that, in ESCC cells, MTA3 represses cancer metastasis and stemness by targeting the SOX2OT/SOX2 axis.Figure 4MTA3 Regulates ESCC Cell Metastatic Potential and Stemness via SOX2OT(A and B) Western blot and qRT-PCR in EC9706 cells transfected with a combination of shMTA3 and SOX2OT AS oligo (A) or MTA3- and SOX2OT-expressing plasmid (B).(C and D) The above-mentioned cells were subjected to the cell invasion assay (C) and sphere assay (D). Representative fields of the invaded cells, and sphere (left panels). Histograms with the fold change in the number of invaded cells and spheres formed by the indicated cells (right panels). Scale bars: 200 μm in (C) and (D).(E) The indicated cells were infected with lentiviruses carrying luciferase and then subjected to RNA extraction followed by qRT-PCR analysis of luciferase gene. The inguinal lymph nodes were extracted and analyzed for the presence of metastatic cells by bioluminescence imaging.(F) EC9706 cells transfected with a combination of MTA3- and SOX2OT-expressing plasmid were infected with recombinant lentiviruses carrying luciferase and injected subcutaneously into the flanks of nude mice (n = 10). The inguinal lymph nodes of the animal were extracted and analyzed for the presence of metastatic cells by bioluminescence imaging.Data were shown as the means of three independent experiments or representative data. Error bars indicate SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by one-way ANOVA with post hoc intergroup comparisons or chi-square test, where appropriate. See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

MTA3-Repressed SOX2OT/SOX2 Axis Is Significant in the Outcomes of Patients with ESCC Cancer {#sec2.6}
-------------------------------------------------------------------------------------------

We conducted qRT-PCR to measure the mRNA levels of MTA3, SOX2OT, and SOX2 in 32 patients with ESCC, and a Pearson\'s correlation analysis showed a significant negative correlation between MTA3 and SOX2OT (r = −0.408, p = 0.021; [Figure 5](#fig5){ref-type="fig"}A) or SOX2 (r = −0.393, p = 0.026; [Figure 5](#fig5){ref-type="fig"}B). In addition, the level of SOX2OT is positively correlated with the mRNA level of SOX2 (r = 0.874, p \< 0.001; [Figure 5](#fig5){ref-type="fig"}C). We have also conducted immunohistochemistry (IHC) to estimate SOX2 in a separate cohort of 125 patients with ESCC. Based on the ROC curve analysis, the samples with IHC score ≥4.5 were categorized into the high-SOX2 group and those with IHC scores \<4.5 were in the low-SOX2 group ([Figure 5](#fig5){ref-type="fig"}D). Kaplan-Meier analyses found that patients with ESCC in the high-SOX2 group had a poorer prognosis than those in the low-SOX2 group (p \< 0.001; [Figure 5](#fig5){ref-type="fig"}E). Correlation analyses also found that tumors with low levels of MTA3 were more likely to have high levels of SOX2 (p \< 0.01; [Figure 5](#fig5){ref-type="fig"}F). These patients with ESCC were stratified into different groups based on the levels of MTA3 and SOX2. Kaplan-Meier analyses found that overall survival of patients in the low-MTA3/high-SOX2 group is significantly worse than those in the high-MTA3/low-SOX2 (p \< 0.001; [Figure 5](#fig5){ref-type="fig"}G), high-MTA3/low-SOX2, high-MTA3/high-SOX2, and low-MTA3/low-SOX2 (p \< 0.001; [Figure 5](#fig5){ref-type="fig"}H) groups. Finally, multivariate Cox regression analyses found that low-MTA3/high-SOX2 (HR, 3.273; 95% CI, 1.815 to 5.901, p = 0.000) can be used as independent prognostic indicators in ESCC patient prognosis ([Table 1](#tbl1){ref-type="table"}). These results indicate that the MTA3-targeted SOX2OT/SOX2 axis plays an important role in not only cancer stemness but also ESCC cancer patient outcomes.Figure 5The Dysregulated MTA3-SOX2OT-SOX2 Axis Is Associated with Metastasis and Poor Prognosis(A--C) Pearson\'s correlations of *MTA3* and *SOX2OT* (A), *MTA3* and *SOX2* (B), *SOX2OT* and *SOX2* (C) in 32 primary human ESCC specimens.(D) ROC curve analysis was performed to determine the cutoff score for the overexpression of SOX2.(E) Kaplan-Meier curves compared the overall survival in patients with ESCC with high and low protein levels of SOX2.(F) Correlation of MTA3 and SOX2 IHC score in 125 primary human ESCC specimens (left panel). Percentage of samples showing low or high SOX2 ratio relative to the levels of MTA3 in 125 cases of human ESCC samples (right panel). Scale bars: left panels, 400 μm; right panels, 100 μm.(G and H) Overall survival in patients with ESCC with tumors with low-MTA3/high-SOX2 (G) or low-MTA3 and other groups (H). \*\*p \< 0.01 by chi-square test.Table 1Univariate and Multivariate Cox Proportional Hazards Model Predicting Survival in ESCCVariablesUnivariate Analysisp ValueMultivariate Analysisp ValueHR (95% CI)HR (95% CI)Gender Male versus Female1.421 (0.730--2.766)0.3011.477 (0.743--2.935)0.266Age ≥60 versus \<601.526 (0.880--2.645)0.1321.547 (0.883--2.711)0.128Histologic grade Poor/Moderate versus Well1.586 (0.879--2.860)0.1261.833 (0.938--3.582)0.076Tumor size ≥5 cm versus \< 5 cm1.237 (0.698--2.191)0.4660.975 (0.544--1.751)0.934Tumor depth T~3~/T~4~ versus T~1~/T~2~3.332 (1.200--9.246)0.0211.529 (0.490--4.775)0.465Lymph node metastasis Positive versus Negative1.484 (0.844--2.612)0.1700.654 (0.327--1.307)0.229Stage Ⅲ versus Ⅰ/Ⅱ3.940 (1.774--8.750)0.0013.297 (1.253--8.675)0.016Combination of MTA3 and SOX2 Low MTA3/High SOX2 versus Others3.738 (2.151--6.498)0.0003.273 (1.815--5.901)0.000[^3]

Targeting the MTA3-SOX2OT/SOX2 Axis Represses Cancer Stemness {#sec2.7}
-------------------------------------------------------------

We decided to examine the roles of MTA3, SOX2OT, and SOX2 individually or in combination in cancer stemness in animal models and explore the potential of targeting MTA3-mediated SOX2OT/SOX2 axis as therapeutic strategies. To do so, we first used EC9706 cells to establish overexpression of MTA3 or SOX2 individually or in combinations ([Figure 6](#fig6){ref-type="fig"}A) as well as knockdown of MTA3 or SOX2 by specific shRNA individually or in combination ([Figure 6](#fig6){ref-type="fig"}B). These cells were subcutaneously injected into nude mice, and the tumor volumes were monitored weekly for 4--5 weeks. The animals were sacrificed at the end of the experiment, and the tumors were dissected and weighed. [Figures 6](#fig6){ref-type="fig"}C and 6D show that the tumors derived from the cells with MTA3 overexpression were significantly smaller/lighter and the tumors derived from the cells overexpressing either SOX2OT or SOX2 were significantly bigger/heavier. In addition, the size/weight of tumors derived from the cells overexpressing MTA3 with either SOX2OT or SOX2 was bigger/heavier than that with MTA3 overexpression alone but smaller/lighter than that with either SOX2OT or SOX2 overexpression. On the other hand, the tumors derived from the cells with MTA3 and SOX2 knockdown were bigger/heavier and smaller/lighter, respectively. The size/weight of the tumors derived from the cells with knockdown of both MTA3 and SOX2 was similar to that of the control ([Figure 6](#fig6){ref-type="fig"}E). Furthermore, results from IHC revealed that the effect of MTA3 on stemness markers was attenuated by overexpression of either SOX2OT or SOX2 ([Figures 6](#fig6){ref-type="fig"}F and 6G). Moreover, shRNA-mediated SOX2 depression markedly abolished the MTA3 depletion-induced alterations of stemness markers ([Figure 6](#fig6){ref-type="fig"}H). More importantly, flow cytometry analyses showed that the decrease of CD44^+^ and SP^+^ cells by MTA3 overexpression was overcome by overexpression of SOX2OT or SOX2 ([Figures 6](#fig6){ref-type="fig"}I and 6J), whereas the MTA3 silencing-induced CD44^+^ and SP^+^ subpopulation was hampered by SOX2 depletion ([Figure 6](#fig6){ref-type="fig"}K). These findings collectively support the notion that MTA3 suppresses ESCC stemness *in vivo* through the SOX2OT/SOX2 axis and SOX2OT is essential for MTA3's repressive function of cancer stemness.Figure 6MTA3 Suppresses Tumor Growth via the SOX2OT-SOX2 Axis in ESCC Cells(A and B) Western blot for MTA3 and SOX2 in EC9706 cells stably expressing MTA3 and SOX2 expression construct (A), or shMTA3 and shSOX2 construct (B). β-Actin is shown as a loading control.(C--E) Growth curves of tumor formation of the EC9706 cells stably expressing MTA3 and SOX2OT (C) or SOX2 (D), or shMTA3 and shSOX2 (E) (upper left panel). Weight (upper right panel) and tumors (lower panel) at the end of the experiments (n = 10 per group).(F--H) EMT and stemness markers in tumors derived from mice models injected with EC9706 cells stably expressing MTA3 and SOX2OT (F) or SOX2 (G), or shMTA3 and shSOX2 (H) detected by IHC. Scale bars: 400 μm in (F--G).(I--K) SP^+^ and CD44^+^ cells in tumors derived from mice models injected with EC9706 cells stably expressing MTA3 and SOX2OT (I) or SOX2 (J), or shMTA3 and shSOX2 (K). Histograms showing the proportion of CD44^+^ cells in the indicated cells (right panels).Data are shown as the means of three independent experiments or representative data. Error bars indicate SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by one-way ANOVA with post hoc intergroup comparisons.

Discussion {#sec3}
==========

The biological and clinical significance of the MTA family members in malignancies has been well established. The levels of these factors have even been proposed as potential diagnostic parameters, and targeting each one of the family members could be potential treatments for different cancers ([@bib31]). However, unlike MTA1 and MTA2, which were mainly involved in cancer progression and metastasis, MTA3 possesses both tumor-suppressing and tumor-promoting properties depending on specific cancer types ([@bib31]). We found that, by targeting the SOX2OT/SOX2 axis, MTA3 represses metastasis and cancer stemness in ESCC. Further mechanistic studies demonstrated that MTA3 is recruited by GATA3 to repress SOX2OT transcription. Given the fact that alterations of MTA3 as well as its downstream SOX2OT/SOX2 axis highly correlate with clinical outcomes and the predictability of prognosis, the levels of MTA3, SOX2, and SOX2OT, especially low-MTA3/high-SOX2, could be used as diagnostic parameters, and targeting either MTA3 or the SOX2/SOX2OT axis could be potential therapeutic strategies in ESCC treatment.

Different research groups including ours have extensively studied the well-established regulatory role of MTA3 in EMT ([@bib31]). We found that MTA3 is significantly downregulated in gastroesophageal junction adenocarcinoma and its downregulation is highly associated with upregulated Snai1 and enhanced EMT ([@bib11]). Accordingly, MTA3 represses ESCC metastasis and cancer stemness. This finding is in line with the fact that MTA3 is capable of inhibiting the initiation of primitive hematopoiesis in vertebrate embryos ([@bib25]), repressing EMT in breast cancer cells ([@bib15]), and suppressing Wnt4 pathway in mammary epithelial cells ([@bib48]), implicating a role for MTA3 in regulation of stem cell properties. More importantly, the results from our gain-of-function and loss-of-function experiments demonstrated that, instead of targeting Snai1, Twist1, Twist2, and ZEB1, MTA3 inhibits ESCC metastasis and cancer stemness by repressing SOX2OT/SOX2 axis. To our knowledge, this is the first report about MTA3\'s regulatory role in cancer stemness in ESCC.

Similar to SOX2, SOX2OT is highly expressed in embryonic stem cells and downregulated upon the induction of differentiation ([@bib35]). The dysregulation of SOX2OT and SOX2 have been noticed in some cancers, including esophageal squamous cell carcinoma ([@bib35]), lung squamous cell carcinoma ([@bib18]), and breast cancer ([@bib1]). Moreover, SOX2OT and SOX2 are co-upregulated in breast cancer cell lines during suspended culturing with enhanced CSC-like properties ([@bib1]). Both SOX2OT and SOX2 have also been reported to promote cancer cell metastatic potential ([@bib26]). Although the roles of SOX2OT in SOX2 regulation are not well established, it appears that SOX2OT regulates SOX2 transcriptionally ([@bib26], [@bib50]). In pancreatic ductal adenocarcinoma, the transcription regulator Yin Yang-1 (YY1) occupies the SOX2OT promoter and suppresses its transcription ([@bib50]). Androgen receptor (AR) binds to the promoter of SOX2OT and modulates RNA polymerase II-driven SOX2OT expression in mouse forebrains and embryonic neural stem cells ([@bib40]). SOX2OT is also regulated by microRNAs such as miR-211 ([@bib34]). Gene amplification and promoter hypomethylation of SOX2OT gene are strongly associated with higher expression of SOX2OT ([@bib6], [@bib18]). We found that MTA3 is recruited by GATA3 to the promoter region of SOX2OT and subsequently represses SOX2OT transcription. Therefore, low levels of MTA3 lead to upregulation of both SOX2OT and SOX2, which ultimately enhances cancer stemness in ESCC.

It has been reported that GATA3 plays an important role in the regulation of CSC activities ([@bib46]) and loss of GATA3 contributes to breast cancer metastasis ([@bib37]). In addition, GATA3 is mutated in \>10% of breast tumors ([@bib51]). Mutations in the second zinc finger domain of GATA3 diminishes or abolishes its DNA-binding ability and reduces its stability in human breast cancers ([@bib42]). These findings altogether suggest that GATA3 mutations are "drivers" of breast cancer development. Of note, MTA3 physically interacts with GATA3 and regulates a subset of genes that control EMT in breast cancer cells ([@bib37]). In this study, we identified a critical role of GATA3 in mediating MTA3-repressed SOX2OT. Of note, genetic changes (mutation, amplification, and deletion) of GATA3 are extremely rare in esophageal cancer (0.62%, [Table S3](#mmc1){ref-type="supplementary-material"}). Therefore, dysfunctional MTA3, not GATA3, likely to be a "driver" in esophageal cancer development and the MTA3/SOX2OT/SOX2 axis, plays an inhibitive role in esophageal cancer stemness.

Given that MTA3 is one of the master regulators of EMT, it is not surprising to find that hundreds of genes were up- or down-regulated by MTA3 ([Figure S6](#mmc1){ref-type="supplementary-material"}A). However, we conclude that SOX2, through the SOX2OT/SOX2 axis, plays an overwhelmingly prominent role in MTA3-regulated cancer stemness based on the following evidence. (1) SOX2 is the only MTA3 target among the stemness-related genes tested ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6C--S6E). (2) Results from the experiments using animal models showed that MTA3 and SOX2OT and/or SOX2 are capable of inhibiting and enhancing tumor growth, respectively. More importantly, the inhibitory effect of MTA3 on tumor growth is SOX2 and SOX2OT dependent ([Figure 6](#fig6){ref-type="fig"}). (3) Both SOX2 and SOX2OT play indispensable roles in MTA3-regulated cancer stemness ([Figures 4](#fig4){ref-type="fig"} and [S8](#mmc1){ref-type="supplementary-material"}). (4) The inverse relationship between MTA3 and SOX2 is not only frequently observed in ESCC tissue but also highly correlated with patients\' overall survival ([Figure 5](#fig5){ref-type="fig"}). Therefore, targeting the MTA3/SOX2OT/SOX2 axis could be an efficacious therapy for the ESCC caused by dysregulation of this axis. In fact, targeting lncRNAs *in vivo* specifically by RNA-targeting therapeutics and LNA appears to be a practically attractive clinical tool ([@bib23]). Therefore, the current study not only identified a previously unrecognized molecular mechanism in MTA3-regulated cancer stemness but also implicated a great potential of the MTA3/SOX2OT/SOX2 axis in diagnosis, prognosis, and treatment of ESCC.

Limitations of the Study {#sec3.1}
------------------------

Based on the results mainly derived from overexpression and/or knockdown of different genes in cultured cells and xenograft mouse models, we were able to demonstrate that, by targeting/repressing the SOX2OT/SOX2 axis, MTA3 can suppress cancer stemness and EMT in ESCC. However, the conclusions would be strengthened if the relevant experiments were conducted in tissue-specific MTA3 transgenic and/or MTA3 knockout mice. However, owing to the lack of esophagus-specific loxP-Cre constructs currently, we will not be able to conduct such animal experiments. Furthermore, the clinical significance of this MTA3-SOX2OT/SOX2 axis needs to be validated in larger clinical cohorts ([@bib45]) ([@bib12], [@bib13]).

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S8, and Tables S1--S3
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